Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT01757639 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

NIH

Sponsor class

Conditions

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome
Previously Treated Myelodysplastic Syndrome
Recurrent Adult Acute Myeloid Leukemia
Secondary Myelodysplastic Syndrome

Interventions

BIOLOGICAL: Ipilimumab
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)